Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
Want to see AU:BGT full AI Analyst Report?
Top Page
Bio-Gene Technology Ltd.
(Sydney:BGT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.02
▲(20.00% Upside)
Action:Reiterated
Date:05/27/26
The score is primarily weighed down by very weak financial performance (zero revenue, persistent losses, and ongoing cash burn with shrinking equity). Technicals are also negative with price below key moving averages and bearish momentum, while valuation is difficult to assess due to losses and no dividend support.
Positive Factors
IP/licensing business model
A licensing-centric model leverages proprietary compounds to scale via partners, enabling revenue without heavy manufacturing capital. Over 2-6 months this supports margin upside if partners commercialize products and reduces capex needs, preserving upside from royalties and milestones.
Negative Factors
Revenue collapse to zero
A complete halt in reported revenue signals failed or delayed commercialization and removes near-term validation of the technology's market fit. Persistently no sales over months raises the probability of continued reliance on financings rather than organic cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
IP/licensing business model
A licensing-centric model leverages proprietary compounds to scale via partners, enabling revenue without heavy manufacturing capital. Over 2-6 months this supports margin upside if partners commercialize products and reduces capex needs, preserving upside from royalties and milestones.
Read all positive factors
Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.85M
Dividend YieldN/A
Average Volume (3M)988.87K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bio-Gene Technology Ltd. Business Overview & Revenue Model
Company Description
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flav...
How the Company Makes Money
BGT generates revenue primarily through licensing its intellectual property, including unique insecticide technologies, to commercial partners in agriculture, public health, and pest control sectors. It collaborates with manufacturers and distribu...
Bio-Gene Technology Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 18.32K | 149.23K | 445.73K | 62.61K |
| Gross Profit | -47.16K | -245.78K | -301.45K | -164.04K | 178.59K | -110.59K |
| EBITDA | -3.32M | -2.58M | -2.97M | -3.14M | -2.92M | -2.85M |
| Net Income | -1.96M | -2.58M | -2.41M | -3.10M | -2.91M | -2.40M |
Balance Sheet | ||||||
| Total Assets | 1.47M | 2.15M | 3.16M | 3.84M | 7.30M | 5.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 1.14M | 2.21M | 2.99M | 6.34M | 3.93M |
| Total Debt | 0.00 | 51.21K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 307.71K | 522.98K | 368.45K | 613.88K | 1.03M | 754.57K |
| Stockholders Equity | 1.17M | 1.63M | 2.79M | 3.22M | 6.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -2.54M | -2.76M | -3.28M | 36.67K | -1.83M |
| Operating Cash Flow | -1.78M | -2.54M | -2.75M | -3.28M | 43.52K | -1.83M |
| Investing Cash Flow | 0.00 | 0.00 | -5.70K | 0.00 | -6.84K | -3.03K |
| Financing Cash Flow | 2.36M | 1.47M | 1.98M | -75.00K | 4.41M | 239.88K |
Bio-Gene Technology Ltd. Technical Analysis
Neutral
0.02
Price Trends
0.03
Negative
0.03
Negative
0.03
Positive
Market Momentum
>-0.01
Positive
45.24
Neutral
53.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.24 is Neutral, neither overbought nor oversold. The STOCH value of 53.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:BGT.
Bio-Gene Technology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$8.27M | -9.89 | -17.07% | ― | ― | -840.00% | |
46 Neutral | AU$11.89M | -2.09 | -218.76% | ― | 76.94% | 42.95% | |
45 Neutral | AU$2.17M | -1.06 | -32.19% | ― | ― | 75.44% | |
44 Neutral | AU$8.85M | -4.35 | -140.35% | ― | ― | ― | |
44 Neutral | AU$10.62M | -1.43 | 1068.18% | ― | ― | 40.85% | |
39 Underperform | AU$5.95M | -1.60 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:BGT
Bio-Gene Technology Ltd.
0.03
<0.01
27.27%
AU:ZLD
Zelira Therapeutics
0.50
0.02
4.17%
AU:IXC
Invex Therapeutics Ltd.
0.11
0.02
18.28%
AU:CMB
Regeneus Ltd.
0.44
0.23
112.20%
AU:1AD
AdAlta Ltd.
―
―
―
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Bio-Gene Technology Ltd. Corporate Events
Bio-Gene Launches Securities Purchase Plan to Raise New Equity Capital
May 26, 2026
Bio-Gene Technology has announced a new securities purchase plan, seeking to issue up to 60 million fully paid ordinary shares and 30 million options, each option expiring on 15 October 2027 with an exercise price of A$0.035. The plan, with a reco...
Bio-Gene Technology Plans Major Share and Option Issue on ASX
May 26, 2026
Bio-Gene Technology Ltd has announced a proposed capital raising via a placement or similar issue on the ASX, planning to issue up to 108,400,000 new ordinary fully paid shares and 57,921,150 options. The options are a new class expiring on 15 Oct...
Bio-Gene outlines natural insecticide strategy in investor briefing
May 26, 2026
Bio-Gene Technology has released an investor presentation outlining its strategy to develop nature-derived insecticides aimed at achieving significant worldwide impact. The document emphasises that the presentation is for general information only,...
Bio-Gene Raises A$3.21m to Advance Flavocide and Qcide Commercialisation
May 26, 2026
Bio-Gene Technology has raised A$2.71 million via a discounted share placement to professional and sophisticated investors, with one free attaching option for every two shares, and will launch a partially underwritten share purchase plan to raise ...
Bio-Gene Shares Halted on ASX Ahead of Proposed Capital Raising
May 22, 2026
Bio-Gene Technology Limited has requested and received a trading halt on its fully paid ordinary shares on the ASX, effective from the start of trading on 22 May 2026. The halt will remain in place until either the company releases a new market an...
Bio-Gene Wins Key U.S. Patent for Flavocide Insecticide Combination
May 6, 2026
Bio-Gene Technology has secured allowance from the United States Patent and Trademark Office for a key patent covering the synergistic use of its Flavocide insecticide with permethrin or pyrethrin. Formal grant is expected within two to four month...
Bio-Gene Advances Flavocide Safety Studies as Qcide Deal Targets Japan’s $1bn Pest Market
Apr 27, 2026
Bio-Gene Technology is progressing two major regulatory studies for its Flavocide natural insecticide, including an extended one-generation reproductive toxicity study in rats and an acute neurotoxicity study, both conducted under OECD and GLP sta...
Bio-Gene appoints MVAB Audit as new external auditor in administrative change
Apr 13, 2026
Bio-Gene Technology Limited has appointed MVAB Audit Pty Ltd as its new external auditor, effective 10 April 2026, following the incorporation of the existing audit practice and with all required regulatory consents in place. The company stressed ...
Bio-Gene Showcases Nature-Derived Insecticide Strategy at 2026 NWR Healthcare Conference
Mar 26, 2026
Bio-Gene Technology used the NWR Virtual Healthcare Conference 2026 to showcase its strategy of developing new insecticides derived from nature for worldwide application. The presentation emphasized its mission to deliver high-impact, nature-based...
Bio-Gene advances Qcide oil production and prepares for large-scale expansion
Mar 9, 2026
Bio-Gene Technology has completed its 15th harvest and extraction of Qcide oil from its far north Queensland plantation, confirming that standardized processing continues to deliver oil meeting commercial specifications. The company’s tree i...
Bio-Gene Targets 2027 APVMA Filing as Flavocide Toxicology Program Advances
Mar 2, 2026
Bio-Gene Technology has reported solid progress in the regulatory development of its novel insecticidal active constituent, Flavocide, with a series of toxicology and metabolism studies advancing according to plan. Early toxicology data have been ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.